

CD36 (N-15): sc-5522

BACKGROUND

CD36 (collagen type I receptor, thrombospondin receptor, FAT, GP4, GP3B, GPIV, PASIV, SCARB3) is a membrane glycoprotein on platelets, monocytes and umbilical vein endothelial cells. CD36 binds to Collagen, Thrombospondin, anionic phospholipids and oxidized LDL. CD36 plays a key role in both phagocytosis and lipid recycling, for constant production of mature spermatozoa. Mutations in this gene cause platelet glycoprotein deficiency. Three alternatively spliced transcript variants encoding the same protein isoform have been found for this gene. Thrombospondins are widely distributed proteins that influence a variety of adhesive processes and CD36 may have important functions as a cell adhesion molecule.

REFERENCES

- Greenwalt, D.E., et al 1992. Membrane glycoprotein CD36: a review of its role in adherence, signal transduction, and transfusion medicine. *Blood* 80: 1105-1115.
- Daniel, J.L., et al. 1994. Collagen induces normal signal transduction in platelets deficient in CD36 (platelet glycoprotein IV). *Thromb. Haemost.* 71: 353-356.
- Alessio, M., et al. 1996. Synthesis, processing, and intracellular transport of CD36 during monocytic differentiation. *J. Biol. Chem.* 271: 1770-1775.
- Navazo, M.D., et al. 1996. Identification of a domain (155-183) on CD36 implicated in the phagocytosis of apoptotic neutrophils. *J. Biol. Chem.* 271: 15381-15385.
- Dawson, D.W., et al. 1997. CD36 mediates the *in vitro* inhibitory effects of Thrombospondin-1 on endothelial cells. *J. Cell Biol.* 138: 707-717.
- Truman, L.A., et al. 2004. Macrophage chemotaxis to apoptotic Burkitt's lymphoma cells *in vitro*: role of CD14 and CD36. *Immunobiology* 209: 21-30.

CHROMOSOMAL LOCATION

Genetic locus: CD36 (human) mapping to 7q11.2; Cd36 (mouse) mapping to 5 A3.

SOURCE

CD36 (N-15) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the N-terminus of CD36 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-5522 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

CD36 (N-15) is recommended for detection of CD36 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).


CD36 (N-15) is also recommended for detection of CD36 in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for CD36 siRNA (h): sc-29995, CD36 siRNA (m): sc-37245, CD36 shRNA Plasmid (h): sc-29995-SH, CD36 shRNA Plasmid (m): sc-37245-SH, CD36 shRNA (h) Lentiviral Particles: sc-29995-V and CD36 shRNA (m) Lentiviral Particles: sc-37245-V.

Molecular Weight of CD36: 88-90 kDa.

Positive Controls: HUV-EC-C whole cell lysate, human platelet extract or RAW 264.7 whole cell lysate: sc-2211.

DATA



CD36 (N-15): sc-5522. Western blot analysis of CD36 expression in platelet (A), hPBL (B) and mPBL (C) whole cell lysates.

SELECT PRODUCT CITATIONS

- Vallbo, C., et al. 2004. The expression of Thrombospondin 1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer. *BJU Int.* 93: 1339-1343.
- Vallbo, C., et al. 2005. Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model. *Acta Oncol.* 44: 293-298.
- Handberg, A., et al. 2006. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of Insulin resistance. *Circulation* 114: 1169-1176.
- Damber, J.E., et al. 2006. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by Thrombospondin. *Cancer Chemother. Pharmacol.* 58: 354-360.
- van Groen, T., et al. 2011. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology. *J. Alzheimers Dis.* 24: 301-313.